• Angelini Pharma is reportedly exploring a potential acquisition of Catalyst Pharmaceuticals, NasdaqCM:CPRX.
• The rumors center on a possible takeover that could affect Catalyst Pharmaceuticals' valuation and control.
• The news comes as Catalyst Pharmaceuticals shares last closed at $28.13.

Catalyst Pharmaceuticals has delivered strong multi year share returns, with the stock up 21.5% year to date and 15.9% over the past year. Looking further back, investors holding over three and five years have seen gains of 68.8% and a very large increase respectively, from a much lower base. The current share price of $28.13 reflects a business that the market already prices with meaningful expectations.

Any confirmed approach from Angelini Pharma would likely refocus attention on control of the company and the value of its existing portfolio. For you as a shareholder or potential investor, the key considerations are deal terms, certainty of funding, and how a possible bid compares with where NasdaqCM:CPRX has traded in recent years. Until there is formal confirmation, it can be useful to evaluate both standalone prospects and the range of possible M&A outcomes.

Stay updated on the most important news stories for Catalyst Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Catalyst Pharmaceuticals.

The reported interest from Italy based Angelini Pharma has pushed M&A into the foreground for Catalyst Pharmaceuticals, after the shares moved nearly 20% on the day of the rumor and the company’s market capitalization sat around US$3.3b. For current holders, the key question is whether any eventual proposal would fairly reflect control of a rare disease portfolio that already supports a US listed business with established products. For Angelini, a bid for Catalyst would fit with its stated goal of expanding beyond European markets and could add a US commercial platform in neuromuscular and rare diseases, where peers such as BioMarin, Vertex Pharmaceuticals and Alexion, now part of AstraZeneca, are active. However, the discussions are described as early, with Angelini also reviewing other targets, so there is no clear line of sight yet on price, structure or timing.

How This Fits Into The Catalyst Pharmaceuticals Narrative

• Potential interest from a larger pharmaceutical buyer lines up with the narrative that Catalyst’s rare disease portfolio and strong payer coverage could be attractive to companies looking to add established assets and cash flow.
• A change of control could challenge the current narrative that focuses on Catalyst as an independent operator using its balance sheet and business development to add products, rather than becoming part of a broader group.
• The possibility that Angelini is weighing several acquisition options, and the uncertainty around any offer price or deal terms, is not fully captured in narratives that concentrate mainly on product momentum and patent risks.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Catalyst Pharmaceuticals to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ There is no certainty that discussions will lead to a formal bid. This means recent share price strength linked to the rumor could fade if talks stall or Angelini focuses on another target.
• ⚠️ Even if a proposal emerges, valuation, regulatory approvals and integration of a rare disease portfolio with concentration in a few key drugs could all be stumbling blocks.
• 🎁 Interest from an acquirer that is actively pursuing growth opportunities can highlight the perceived quality and cash generation of Catalyst’s existing products.
• 🎁 A competitive process, if other bidders emerge, could support negotiations on price and deal terms that reflect the value of control rather than just the pre rumor trading range.

What To Watch Going Forward

From here, the focus is on any confirmation from either company, including whether Angelini or Catalyst comments on the status of talks, hires additional advisers, or outlines deal priorities during upcoming events such as the May 2026 earnings call. Investors should also watch how the share price behaves if there are periods of silence, as that often reveals how much of the current valuation is tied to M&A expectations versus the ongoing Firdapse and Agamree story.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Catalyst Pharmaceuticals, head to the community page for Catalyst Pharmaceuticals to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.